Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has scheduled a board meeting on 7 August 2026 to consider and approve the unaudited standalone financial results for the first quarter ended 30 June 2026.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has announced its 41st Annual General Meeting to be held on August 21, 2026, through Video Conferencing and remote e-voting facility. The company has also disclosed its unaudited financial results for the quarter ended June 30, 2026, showing a revenue from operations of ₹4,170.47 crore and a net profit for the period of ₹274.57 crore.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd announced its 41st AGM will be held on 21st August, 2026. The company highlighted its 41-year history, built on relationships with healthcare professionals and patients. It showcased its 50 brands across 125 products and 10 therapeutic areas, with a focus on pediatric care and respiratory solutions. The company emphasized its strong market presence, consistent quality, and dependable outcomes.

Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has released its annual report for FY 2025-26, highlighting its 40-year journey of building relationships with healthcare professionals and creating a portfolio of 50 brands across 125 products and 10 therapeutic areas. The company's flagship brand, TYNOL, has maintained its market presence and growth potential, while ACOLATE has earned the trust of doctors and medical practitioners. The company aims to strengthen growth across its respiratory franchise in FY 2027.